Prioritizing health:

A Prescription for
Prosperity
McKinsey Global Institute
July 2020

CONFIDENTIAL AND PROPRIETARY

Any use of this material without specific permission of McKinsey & Company
is strictly prohibited
Today’s speakers . . .

Jaana Remes Katherine Linzer Kana Enomoto

Partner, San Francisco Partner, Chicago Senior Expert, Washington, D.C.

[email protected] [email protected] [email protected]

An economist and a Partner at the A leader of the Firm’s state healthcare practice, Co-leads the Firm’s Center for Societal Benefit
McKinsey Global Institute (MGI), leads focuses on health and human services strategy and through Healthcare, which invests in research
research on health, productivity, special needs populations across U.S. states and and mitigating social determinants of health,
competitiveness, and urbanization payers rural health, maternal health, and behavioral
health – including mental health and
Advises global business and government Collaborates with states and healthcare payers on substance use
leaders on issues related to her areas of healthcare strategy and innovation, with a focus on
research and expertise the Medicaid and long-term care populations Serves clients on optimizing the delivery of
behavioral-health services, improving public
Has authored numerous articles and reports Previously served as a Fellow with McKinsey’s health, and increasing the impact of advocacy
referenced by leading publications, Health Systems Institute in London, where she programs
including “Prioritizing health: A prescription served health systems in Europe, Asia, and
for prosperity” Australia Previously served as Acting Administrator of
the Substance Abuse and Mental Health
Contributes to policy debates and frequently Has authored numerous healthcare-related articles, Services Administration and Chief of Staff to
speaks at industry conferences including “The Medicaid Agency of the Future” the Surgeon General of the United States

McKinsey & Company 2

Life expectancy has increased dramatically over the last 80 years

+42
72.8

years

Global life
expectancy 30.5
years

1810 1840 1870 1900 1930 1960 1990 2020

1 Health Human Productivity and Long-Term Economic Growth, Arora 2001

2 Health’s Contribution to Economic Growth in an Environment of Partially Endogenous Technical Progress from 1960 -1990
3 MGI backward looking analysis assuming constant mortality and morbidity rates from 1990 until 2017
4 To be calculated; current hypothesis

McKinsey & Company 3

We are living longer… but not always in better health
Change 2007–17, years
Change in life expectancy between 2007 and 2017 Life expectancy, 2017
Years Years
In good health In poor health Loss in life expectancy

Japan 0.9 0.7 1.6 83.0

France 1.4 0.1 1.5 81.7

United Kingdom 0.8 0.9 1.7 80.3

Germany 0.3 1.1 1.4 80.3

USA 0.5 0.5 78.2

Mexico -0.3 76.1

China 1.3 1.6 2.9 76.3

India 2.7 1.1 3.8 70.2

McKinsey & Company 4

Looking ahead, age-and lifestyle-related diseases is expected to rise
while many infectious diseases could decrease significantly
Disease Baseline Forecast
Change in disease burden between 2020 and 2040 globally
% change in disease burden measured in DALY1 Infectious diseases Bubble size: 2020 disease burden, DALYs1

80
70
60 Neurological disorders Diabetes and kidney diseases
Substance use disorders
50
Musculoskeletal disorders Vision and hearing loss
40
Skin diseases Chronic respiratory
30
diseases
20 Other NCDs
Digestive diseases Cancers
10
Self-harm/ interpersonal violence Mental disorders Unintentional injuries
0
HIV/AIDS and STIs
-10 Transport injuries Respiratory infections and TB Cardiovascular
-20 Maternal/ Nutritional deficiencies
diseases
neonatal
-30 Tropical diseases and malaria
-40 Other infectious diseases Diarrhea and intestinal infections
-50
Lower likelihood with age Higher likelihood with age

1. DALY = disability-adjusted life year

Source: Global Disease Burden Database Institute for Health Metrics and Evaluation (IHME); University of Washington (this vie w excludes McKinsey & Company 5
"Other non-communicable diseases"); McKinsey Global Institute analysis
 How much could we improve What is the potential from
health with interventions we innovation in the visible
know work? pipeline?

What would the

benefits be from
improving What would be the economic What would it take to achieve
the healthy growth path?
prize?
health globally?

McKinsey & Company 6

Using interventions that already exist today, the global disease
burden could be reduced by about 40 percent over the next
two decades
Disease burden impact by 2040
% of disability-adjusted life years (DALYs)

Global disease
100%
burden

Disease burden Aspirational yet realistic with

reduction in
healthy growth
41% adoption rates adjusted by
scenario country income archetype

Remaining unmet
59%
disease burden

1 Based on evidence from Australia. Greenhalgh, Elizabeth, Michelle Scollo, and Margaret Winstanley, Tobacco in Australia: Facts and issues, Cancer Council Victoria, 2020. McKinsey & Company 7
Source: Global Burden of Disease Database 2016 IHME; McKinsey Global Institute analysis
The potential to reduce the disease burden varies significantly by
disease type: Chronic conditions are more challenging to tackle

Diseases burden reduction Disease burden reduction in

potential by 2040 Healthy growth scenario
Healthy lifespan scenario Remaining burden Infectious diseases Million DALYs1

Diarrheal and intestinal infections 86% 82

HIV/AIDS and sexually transmitted infections 75% 49
Maternal and neonatal disorders 71% 120
Respiratory infections and tuberculosis 67% 107
Neglected tropical diseases and malaria 63% 39
Digestive diseases 57% 49
Nutritional deficiencies 56% 31
Other infectious diseases 46% 26
Vision and hearing loss 44% 29
Chronic respiratory diseases 40% 45
Cardiovascular diseases 39% 140
Other non-communicable diseases 35% 42
Diabetes and kidney diseases 31% 32
Skin and subcutaneous diseases 30% 12
Cancers 28% 66
Transport injuries 26% 19
Unintentional injuries 26% 27
Neurological disorders 23% 26
Substance use disorders 22% 10
Musculoskeletal disorders 21% 28
Self-harm and interpersonal violence 21% 14
Mental health disorders 14% 17

1. DALY = disability-adjusted life year; list represents all 22 level 2 disease burden according to IHME.

Source: Global Burden of Disease Database 2017 IHME; McKinsey Global Institute disease reduction model McKinsey & Company 8
65 is the
new 55
A 65-year-old in a healthy growth scenario
has the same likelihood to be as healthy as
a 55-year-old in baseline scenario

McKinsey & Company 9

Over 70% of the health improvement potential from known
interventions would come from environmental, social, behavioral
and preventive interventions
Environmental, social
and behavioral Therapeutic
Dietary interventions 9% Anti-infective 10%
medicines1
Education for behavioral 7%
change 28 Specialist surgery 5%
34
Smoking cessation 4% Psychological 3%

Prevention and
health promotion
Vaccines 11%

70%
Safe child birth 9%
Medicines for heart 7% 38
disease, stroke
prevention, and diabetes

1. 84% of impact comes from low and lower middle income countries

Source: Global Burden of Disease Database 2017 IHME, McKinsey Global Institute analysis McKinsey & Company 10
40%
of health improvements
could be achieved at
under $100 for each
additional healthy life
year

McKinsey & Company 11

Even in high-income countries, almost 60% of health improvements
would come at under $1,000 for each additional healthy life year

Environmental, social and behavioral Prevention and health promotion Therapeutic

High-income countries
Cost-Effectiveness
Cost per DALY averted, ($, log scale)1

100000

10000
Almost 60 percent of health gains can be
achieved at under $1,000 for each additional
healthy year
1000 1000

102

10

0
Blood pressure and Behavior change Sight tests and glasses Treatment for Road safety measures
cholesterol reduction 2 to reduce Triptan and other Hearing aids drug use disorders Group-based multi-modal
cardiovascular risk2 medicines for migraine Acute stroke care program for back pain
Diabetes prevention program Smoking cessation
Targeted lung cancer screening
Diabetes medicines and disease management (education, monitoring)
Cumulativ e health improv ement
DALYs averted (millions)1

Note: Interventions are ordered in ascending order of cost for every healthy life year. The higher the disease burden reducti on potential, the larger the width
under each intervention.
1.DALY = disability-adjusted life year.
2.Pharmacological prevention of cardiovascular disease includes use of antihypertensives and statins (and/or other cholesterol -lowering medicines).
Cardiovascular lifestyle education includes physical activity, diet, smoking cessation, and alleviation of other risks. These interventions are delivered as a
combined program.

Sources: Institute for Health Metrics and Evaluation, used with permission, all rights reserved; WHO, “Updated Appendix 3 of the WHO Global NCD Action Plan 2013-2020: Technical
Annex (Version dated 12 April 2017)”, 2017; “Disease Control Priorities 3 (DCP-3): Economic evaluation for Health,” University of Washington Department of Global Health, 2018; Tuf ts
Cost-Effectiveness Analysis Registry; McKinsey Global Institute analysis
 How much could we improve What is the potential from
health with interventions we innovation in the visible
know work? pipeline?

What would the

benefits be from
improving What would be the economic What would it take to achieve
the healthy growth path?
prize?
health globally?

McKinsey & Company 13

Some diseases have limited effective prevention and therapeutic
interventions, for example, cardiovascular diseases, cancers, and mental
and neurological disorders
Disease burden impact Disease burden by disease group
% In % of remaining disease burden

100% 41%
Cardiovascular diseases
15

Mental and
59% neurological
13
16 other disease disorders
groups 49

11
Cancers

7
5
Musculoskeletal
Other non-communicable disorders
Global disease burden Potential disease Remaining diseases
burden reduction disease burden
from healthy
growth scenario

Source: Global Burden of Disease Database IHME; MGI disease reduction model McKinsey & Company 14
 Omics and molecular Innovative Vaccines
technologies Cholesterol-lowering
CRISPR and curbing malaria vaccine

Innovations in
the visible
pipeline that
may enter the
Next-generation
market by Pharmaceuticals Advanced Surgical

2040…
Senolytics and regulation Suspended animation for
of cellular aging severe trauma patients

Cell Therapy and

Regenerative Medicine
CAR-T Cell therapy
for solid tumors

McKinsey & Company 15

 Connected and Electroceuticals
cognitive devices Implantable microchip
E‐Tattoo for mitigating chronic pain
Heart Diagnostics

…could further
reduce disease
burden by Robotics and Prosthetics
Exoskeleton suit

6-10%
Tech-enabled for mobility support
care delivery
Multichannel
care delivery

Digital therapeutics
AI-powered app to
enable behavior change

McKinsey & Company 16

 How much could we improve What is the potential from
health with interventions we innovation in the visible
know work? pipeline?

What would the

benefits be from
improving What would be the economic What would it take to achieve
the healthy growth path?
prize?
health globally?

McKinsey & Company 17

Better health impacts GDP through four channels

Fewer early Preventing premature deaths to extend active life

Better health deaths

Fewer health Reducing disability in the potential labor force

conditions

Expanded Enabling people to stay in workforce longer

participation Increasing participation of people with disabilities
Increasing participation of informal caregivers

Increase in Boosting productivity of current workforce

productivity Improving children’s health to boost productivity as adults

McKinsey & Company 18

The potential GDP impact
globally in 2040:

$12 8%
trillion of GDP

0.4 ppt
additional growth
2020–40
A majority of the increase in GDP would come from people
suffering fewer health conditions and expanded participation
$ trillion,1 2040

2.0 153.7
4.1

4.2

1.4
142.0

Base case Fewer early deaths Fewer health Expanded Increase in Potential GDP
GDP 2040 conditions participation1 productivity 2040

Annual
Growth Rate 2.6% 3.0%
2020-2040

1. Includes impact on older adults (only high income and upper middle income), informal caregivers (only in OECD due to data availability), people with disability (global).

Source: Global Burden of Disease Database 2016 IHME; Oxford Economics; ILO Stat; McKinsey Global Institute analysis McKinsey & Company 20
Almost 70% of the healthy life years we estimate are added to those
under 70 where the economic contribution is the highest
Global perspective, healthy growth scenario

Additional healthy life years lived in 2040

and respective GDP impact by age group

Age 0 20 40 60 80
70.7
59.0 63.8 60.1
44.2 43.8 49.2
40.5
34.2
19.8 Additional healthy
life years1, million

0 0.2
0.4 0.7 0.6 GDP impact in 2040,
$ trillion
1.4 1.6 1.6
1.7

3.4

1. Additional healthy life years from averting deaths and reducing disability.

Source: Global Burden of Disease Database 2016 IHME; Oxford Economics; ILO Stat; OECD; EUROSTAT; National Transfer Accounts P roject; McKinsey & Company 21
McKinsey Global Institute model
The economic benefits are driven by differences in the
underlying health outcomes and labor market structures of
countries
GDP Impact breakdown, 2040 Increase in productivity Fewer health conditions
Healthy growth scenario, % and $ trillion Expanded participation Fewer early deaths

3.3 0.2 2.3 2.9 0.7 0.5 0.7 0.4

0.7
17 19 14 16 16 20 19
21
21
2 4
30 19
39 41 19
43 53 41
51

39 42 48
33 33
33
29 36
27
11 6 14 10 14 12
5
US & Canada Australasia Western Europe East Asia Eastern Europe Latin America Middle East & South Asia Sub Saharan
& Central Asia North Africa Africa

Higher GDP per capita Lower GDP per capita

Source: Global Burden of Disease Database IHME; Oxford Economics; ILO Stat; OECD; EUROSTAT; National Transfer Accounts Projec t; MGI Model McKinsey & Company 22
The
$100 >$3 $20-30
societal trillion trillion billion
benefits
Economic welfare Reduction in the social Incremental value
unlocked through and economic costs of volunteering time
additional years lived of mental health for 65+
are likely
to far 21 230
exceed the
days
65% million
economic Average additional Reduction in child More people

impact days of better

health per year
mortality (<5 years)
by 2040
living in 2040

Source: Global Burden of Disease Database 2016 IHME; OECD; The Lancet McKinsey & Company 23
Commission on global mental health and sustainable development; Gallup;
MGI Model
For each $1 invested in improving health, an economic return
of $2 to $4 is possible
Healthy growth Scenario, 2040, USD trillions

High income Upper middle Lower middle Low income

countries income countries income countries countries
​Additional
health-care 1.5 1.4 0.4 0.1
spending

​GDP impact 4.6 2.8 1.4 0.2

3x 2x 4x 2x

Welfare
18.6 41.0 54.2 16.4
gains

Note: Snapshot view of the healthy growth scenario in 2040. Additional healthcare spending, GDP impact and welfare gains directly attributable to better health only (excluding expanded participation)

Source: Institute for Health Metrics and Evaluation, used with permission, all rights reserved; Oxford Economics; ILOSTAT; National Transfer Accounts Projects; WHO, “Updated Appendix 3 of the WHO Global NCD Action plan 2013-2020: Technical annex (version dated McKinsey & Company 24
12 April 2017)”, 2017; “Disease control priorities 3 (DCP-3): Economic Evaluation for Health,” University of Washington Department of Global Health, 2018; Tufts cost-Effectiveness Analysis Registry; McKinsey Global Institute analysis
 How much could we improve What is the potential from
health with interventions we innovation in the visible
know work? pipeline?

What would the

benefits be from
improving What would be the economic What would it take to achieve
the healthy growth path?
prize?
health globally?

McKinsey & Company 25

 Make healthy Keep health Transform Double
growth a social on everyone’s healthcare down on
and economic agenda systems innovation
priority

McKinsey & Company 26

Thank you for your
participation
You can download the report here:
mckinsey.com/prioritizinghealth
Reimagining
healthcare in response
to COVID-19
McKinsey Center for Societal Benefits
through Healthcare
July 2020

CONFIDENTIAL AND PROPRIETARY

Any use of this material without specific permission of McKinsey & Company
is strictly prohibited
The Center for Societal Benefit through Healthcare aims to drive
positive innovation in areas that are critical for the benefit of society

Initial focus areas The Center is a global network of experts, combining McKinsey’s business insights with
leading thinking across five focus areas
Each year, 1 in 5 adults experiences a mental illness, and one in two will
Behavioral Mental experience one at some point in their lives. Those with poor mental health
Health Health are four times more likely to have multiple unmet social needs. As with
Conduct and physical health, racial/ethnic minorities have less access to mental
share pathbreaking
healthcare and are less likely to receive high-quality care when treated.
research in initial
focus areas ~20 million adults have a substance use disorder; more than 130 people
Substance in the United States die every day after overdosing on opioids. Though
opioid use disorder rates are similar across racial groups, there is a 35:1
Partner with Use
Continue
ratio of white patients receiving a buprenorphine Rx vs. patients of another
organizations
to convene to focus on race/ethnicity.
and support Mission achieving One in six Americans – 46 million people – live in rural areas. There is a
multi- tangible significant gap in health between rural and urban Americans, with rural
stakeholder impact Rural Health Americans more likely to die from conditions such as heart disease, cancer,
collaborations and opioid overdoses; disparities in health access and outcomes also exist
by race/ethnicity.
Co-invest with
organizations to launch
Nearly 40% of health outcomes are based on underlying social factors
innovations and share such as economic stability, employment, education, food security, housing,
Social Determinants transportation, social support, and safety. In addition, factors such as race
results so others can
replicate or ethnicity can influence health status and the level of unmet social need.
Over the past two decades, maternal mortality rates in the US have
Maternal Health increased by 50-70%, and rates of severe maternal morbidity have more
than doubled. Pregnancy-related mortality ratios for Black women with at
least a college degree are five times as high as white women with a similar
education.
McKinsey & Company 29
Mental and substance use disorders affect a substantial number of
individuals across the world

Almost 1 billion people

Bubble size: 2020 disease burden, DALYs1 Mental and substance use disorders

worldwide suffer from mental Change in disease burden between 2020 and 2040 globally,
and substance use disorders, % change in disease burden measured in DALY 2
including more than 200 million
80
children1
70 Diabetes and kidney diseases
Globally, the disease burden Neurological
60
disorders Vision and hearing loss
from mental and substance use Substance use disorders
50
disorders is projected to Musculoskeletal
increase by ~20% and
40 disorders
Other NCDs Chronic
Skin diseases Cancers respiratory
~45% respectively, before 30
Maternal/ Self-harm/ diseases
accounting for the impact of 20 neonatal interpersonal
COVID-19 on exacerbating violence Digestive diseases
10
Mental disorders
these conditions 0
HIV/AIDS Unintentional injuries
and STIs
-10 Nutritional deficiencies
Children affected by mental Respiratory infections and TB Cardiovascular
health problems go on to earn -20 Transport injuries
diseases
20% less than their peers, -30 Tropical diseases Enteric infections
the result of diminished and malaria
-40
educational attainment and Other infectious diseases
-50
additional challenges in finding
Lower likelihood with age Higher likelihood with age
and retaining employment
1. Institute for Health Metrics and Evaluation | 2. Disability adjusted life years

Source: Prioritizing health – a prescription for prosperity, MGI, July 2020 McKinsey & Company 30
Mental and substance use disorders are increasingly relevant
across generational cohorts

In the United States, we have seen a…

Baby
Gen Z Millennials Gen X Boomers

126% 47% 300% 75%

increase in post- growth in major increase in drug increase in the
traumatic stress depression diagnoses overdose deaths in the number of older adults
disorder diagnoses for commercially-insured 45-54 age group living alone between
among teenagers millennials between between 1999 and 2000 and 20194,
between 2013 and 2013 and 20162 20173 contributing to
20171 loneliness and low
social connectedness
1. Athenahealth – Pediatric PTSD as a Diagnosis, 2018 | 2. The Health of America Report – Major Depression: The Impact on Overall Health, 2018 | 3. CDC – Drug Overdose Deaths in the United States, 1999– McKinsey & Company 31
2017 | 4. U.S. Census Bureau, American Community Survey – Living arrangements of adults 65 to 74 years old, 1967 to present
COVID-19 could drive a ~50% increase in the prevalence of mental
and substance use disorders, potentially leading to ~20-30% (i.e.,
$100B to $140B) of additional spend in the US alone
Behavioral health care spend Physical health care spend

Anticipated prevalence of mental and substance Potential changes in total spend for people with mental and
use disorders pre and within 12 months post substance use disorders before and during first year post
COVID-191, % of total population COVID-191,2,3, $ billions
30% $611
$569
$78
+21% $66 +30%
+50% $470
20% $43

$503 $534
$427

Pre COVID-19 Post COVID-19 Pre COVID-19 Post COVID-19 (Low) Post COVID-
19 (High)
1. Analysis includes claims data from the Medicare FFS Limited Data Set from the Centers for Medicare & Medicaid Services, de identified Medicaid data, and the International Business Machines Corporation’s Truven MarketScan Commercial
Database. Any analysis, interpretation, or conclusion based on these data is solely that of the authors and not International Business Machines Corporation

2. This does not include Tricare, individual market, or uninsured populations | 3. Accounts for reduction in spend for people losing employment and not gaining Medicaid coverage McKinsey & Company 32
The potential to reduce disease burden from mental and substance
use disorders is hindered by systemic barriers
Diseases burden reduction potential by 2040 in the “healthy lifespan” scenario, based on 2017 Disease burden reduction in
disease burden1, % Healthy lifespan scenario
Mental and substance use disorders Million DALYs 2

Enteric infections 86% 82

HIV/AIDS and sexually transmitted infections 75% 49
Maternal and neonatal disorders 71% 120
Respiratory infections and tuberculosis 67% 107
Neglected tropical diseases and malaria 63% 39
Digestive diseases 57% 49
Nutritional deficiencies 56% 31
Other infectious diseases 46% 26
Sense organ diseases 44% 29
Chronic respiratory diseases 40% 45
Cardiovascular diseases 39% 140
Other non-communicable diseases 35% 42
Diabetes and kidney diseases 31% 32
Skin and subcutaneous diseases 30% 12
Neoplasms 28% 66
Transport injuries 26% 19
Unintentional injuries 26% 27
Neurological disorders 23% 26
Substance use disorders 22% 10
Musculoskeletal disorders 21% 28
Self-harm and interpersonal violence 21% 14
Mental disorders 14% 17
1. List represents all 22 level 2 disease burden according to IHME | 2. DALY = Disability Adjusted Life Year
Source: Prioritizing health – a prescription for prosperity, MGI, July 2020 McKinsey & Company 33
These systemic barriers are underpinned by a set of cross-cutting,
but actionable challenges
Behavioral health care faces a range of
These challenges are evidenced by the fact that:
challenges, including:
Shortage of behavioral health professionals 63% of US counties have a shortage of psychiatrists 1; only 8% of
and physical health professionals with medical schools have a required course on addiction2
behavioral health competency
Inadequate reimbursement policies and Reimbursements were ~20% lower for behavioral healthcare
under-funding of behavioral health services than for primary care in 20173

Lack of scale for evidence-based Only 5% of adolescents with first episode psychosis and 10% of
interventions for mental and substance preschoolers with ADHD receive guideline-concordant care 4
use disorders
Poor integration of physical health, Individuals reporting poor mental health are 1.9x as likely to
behavioral health, and social determinants report not receiving the healthcare they need, and 2.5x as likely
of health to report having multiple unmet social needs5

Low levels of behavioral health literacy 37% of Americans view opioid use disorder as a personal
and lingering stigma relating to mental and weakness and not a disease6; 53% of psychiatrists report
substance use disorders discriminatory attitudes from other providers to patients7
1.McKinsey Vulnerable Populations Dashboard | 2. Surgeon General - Facing Addiction in America, 2016 | 3. Milliman Research - Number of Psychiatrists Rising, but 1-in-5 Children Still Live in County Lacking a Psychiatrist, 2019 | 4. Variability in ADHD Care in Community-
Based Pediatrics, 2014 | 5. McKinsey Consumer Mental Health Survey, 2019 | 6. Politico/ Harvard T.H. Chan School of Public Health 2018 | 7. Canadian Psychiatric Association

McKinsey & Company 34

Today, multiple points along the behavioral
health care continuum are over-burdened, while
others are under-utilized or under-developed

Residential
treatment services

Mental Mental illness Early Outpatient A well-functioning

health and substance intervention services Crisis system that optimizes
promotion use disorder systems
prevention access, affordability,
quality, and experience
Relapse requires adding
prevention capacity as well as
increasing access to
under-utilized and
Emergency under-developed points
Long-term services of care
residential care

Recovery Inpatient
Over-burdened support treatment
Under-utilized/ under-developed services
McKinsey & Company 35
Stakeholders must work together to address these challenges and
optimize the current state of behavioral health care
Detail follows
The emerging vision for behavioral health would include:

Adequate behavioral health professionals and increased behavioral

health competency of physical health professionals

Reimbursement policies that align incentives to increase network

participation and optimize total cost of care

At-scale availability of evidence-based interventions to ensure access

to high-quality behavioral health care when, how, and where people need it

Tech-enabled end-to-end integration of physical, behavioral, and

social determinants of health in primary and specialty care

Behavioral health needs addressed with the same urgency, skill, and
compassion as physical health
McKinsey & Company 36
We are supporting Shatterproof in their development and
execution of a national strategy to reduce the stigma around
opioid addiction
is a national non-profit organization dedicated to reversing the addiction crisis in the United States

Why opioid Nearly 1 in 3 people know someone addicted to opioids. Every 11 minutes someone dies from an
addiction? opioid overdose (more than deaths from car crashes). Even though it is a preventable, treatable health
condition, only 1 in 5 people with an opioid addiction get care they need.

Why does The consequences of stigma include lower rates of diagnosis, poorer quality of treatment, and a
stigma more difficult road to stable recovery
matter?

What is the Society…

overarching • views and treats opioid addiction as a chronic disease
vision? • views and treats evidence-based treatment for opioid addiction – including medications for opioid
use disorder – as useful and necessary
• views and treats people addicted to opioids with respect and compassion
… just as it does for other chronic illnesses like diabetes or cancer – all so more people lead
productive, fulfilled lives
McKinsey & Company 37
Shatterproof Stigma Report

Shatterproof recently released the

The report includes specific action plans to engage employers
Stigma Report, a comprehensive plan to
across the country in this movement
reduce stigma related to opioid use disorder

Educate ❑ Sharing stories: Implement campaigns sharing stories

through using contact- based strategies connecting those with
empowerment OUD and those without OUD
❑ Education: Implement education program to educate on
six specific topics related to addiction

Affirm through ❑ Language: Initiate standards to remove stigmatizing

cultural change language across all communications
and norm- ❑ Events: Participate in recovery-focused community
setting events

Support ❑ Sponsorship: Establish an executive-level sponsor

through policy accountable for advocating for employees with OUD and
improving their workplace environment
❑ Benefits: Align organization health benefits and
guidelines to better support those with OUD

McKinsey & Company 38

Recent publications

May 20, 2020 | Article April 24, 2020 | Podcast April 2, 2020 | Article February 20, 2020 | Survey February 14, 2020 | Survey
The implications for Changing views on Returning to resilience: Understanding the Insights on mental
COVID-19 for mental and substance The impact of COVID- impact of unmet social health from a 2019
vulnerable populations use disorders: An 19 on mental health and needs on consumer McKinsey Consumer
interview with Patrick substance use health and healthcare Survey
Kennedy

McKinsey’s open- Former congressman, As governments race to Income, employment, McKinsey conducted a
access dashboard looks Patrick Kennedy, contain COVID-19, it is education, food security, national survey to
at individuals with discusses mental and important to know the housing, transportation, understand the impact
physical or behavioral substance use disorders actions society can take safety, and social of unmet social needs
health vulnerability and and how healthcare to mitigate the support are all factors on consumer health
their risk for developing stakeholders can help behavioral health impact that affect health and outcomes, utilization,
COVID-19. these populations of the pandemic and well-being. and preferences.
especially during the economic crisis.
COVID-19 pandemic.

McKinsey & Company 39

The Center for Societal Benefit through Healthcare

Center leaders Center website

Tom Latkovic
Senior Partner, Cleveland
[email protected]

Erica Coe
Partner, Atlanta
[email protected] Vulnerable populations dashboard
Key features:

Interactive map at the county or state-

Kana Enomoto level, with dual-axis functionality
Senior Expert, Washington, DC
[email protected] Data download for underlying data
source

Use case driven auto-filtering

McKinsey & Company 40

Thank you for joining today’s webcast!

Questions? Please reach out . . .

Jaana Remes Katherine Linzer

MGI Partner, San Francisco Partner, Chicago

[email protected] [email protected]

Kana Enomoto Mike Roberto

Senior Expert, Washington, D.C. Alumni Relations Manager, Cleveland

[email protected] [email protected]

For general inquiries, please contact [email protected]

McKinsey & Company

 Alumni Directory: Search for alumni and Firm members by name, office,
company, and many other criteria using search and filtering capabilities

Career Services: Access and post job opportunities, indicate an interest

Alumni Website in new roles, and access best practice transition resources
resources
News & Insights: Read a variety of alumni and Firm news, access the
latest Firm thinking, and search the webcast library

Events: See upcoming events around the world and register for
upcoming Alumni Webcasts

Questions: please contact us at [email protected]

McKinsey & Company 42